Profitability
This table compares Graybug Vision and ObsEva’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Graybug Vision | N/A | -77.61% | -71.34% |
| ObsEva | N/A | -416.36% | -92.01% |
Insider & Institutional Ownership
49.9% of Graybug Vision shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by company insiders. Comparatively, 14.4% of ObsEva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Graybug Vision has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Graybug Vision | $426.96 million | 0.00 | -$35.60 million | ($24.23) | -0.02 |
| ObsEva | N/A | N/A | -$58.38 million | ($0.92) | N/A |
Graybug Vision has higher revenue and earnings than ObsEva. Graybug Vision is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.
Summary
Graybug Vision beats ObsEva on 6 of the 9 factors compared between the two stocks.
About Graybug Vision
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
About ObsEva
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
